PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21067460-6	2010	Desvenlafaxine has clinically insignificant effects on the activity of CYP and P-gp.	Desvenlafaxine Succinate	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74	
19127490-3	2009	Unlike various other antidepressants including venlafaxine, desvenlafaxine is not metabolized by cytochrome p450 (CYP) enzyme pathways and is associated with minimal inhibition of CYP enzymes.	Desvenlafaxine Succinate	60-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183	
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	138-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69	
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	138-160	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74	
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-69	
16958828-2	2006	It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV).	Desvenlafaxine Succinate	162-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-74	
19629022-6	2009	CONCLUSIONS: Considering in vitro and available clinical data, desvenlafaxine and venlafaxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6.	Desvenlafaxine Succinate	63-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	257-260